MPG.eBooks - Search Results

1

Pharmacoeconomic review report: Burosumab (Crysvita), Kyowa Kirin Limited : indication : for the treatment of x-linked hypophosphatemia in adult and pediatric patients one year of...

Published 2020

Canadian Agency for Drugs and Technologies in Health

Subjects: “...Cost-Benefit Analysis...”

Read Now

2

Pharmacoeconomic review report: Tocilizumab (Actemra) (Hoffman-La Roche Limited)

Published 2018

Canadian Agency for Drugs and Technologies in Health

Subjects: “...Cost-Benefit Analysis...”

Read Now

3

Pharmacoeconomic review report: Tocilizumab (Actemra) (Hoffman-La Roche Limited)

Published 2018

Canadian Agency for Drugs and Technologies in Health

Subjects: “...Cost-Benefit Analysis...”

Read Now

4

Effect of oseltamivir (TamifluR) for the prevention and treatment of influenza during an influenza pandemic

by Mørland, Berit
Published 2005

Norwegian Knowledge Centre for the Health Services

Subjects: “...Cost-Benefit Analysis...”

Read Now

5

CADTH Canadian Drug Expert Committee recommendation: Brolucizumab (Beovu -- Novartis Pharmaceuticals Canada Inc.) : indication : treatment of neovascular (wet) age-related macular...

Published 2020

Canadian Agency for Drugs and Technologies in Health

Subjects: “...Cost-Benefit Analysis...”

Read Now

6

CADTH Canadian Drug Expert Committee recommendation: Vedolizumab (Entyvio -- Takeda Canada Inc.) : indication : for the treatment of adult patients with moderately to severely acti...

Published 2020

Canadian Agency for Drugs and Technologies in Health

Subjects: “...Cost-Benefit Analysis...”

Read Now

7

CADTH Canadian drug expert committee recommendation: Burosumab (Crysvita -- Kyowa Kirin Limited) : indication : treatment of x-linked hypophosphatemia

Published 2020

Canadian Agency for Drugs and Technologies in Health

Subjects: “...Cost-Benefit Analysis...”

Read Now

8

Long-term use of ranibizumab for the treatment of age-related macular degeneration : a review of the clinical and cost-effectiveness and guidelines

Published 2014

Canadian Agency for Drugs and Technologies in Health

Subjects: “...Cost-Benefit Analysis...”

Read Now

9

Pharmacoeconomic review report: Ixekizumab (Taltz) (Eli Lilly Canada Inc.) : indication : treatment of adult patients with active psoriatic arthritis who have responded inadequatel...

Published 2018

Canadian Agency for Drugs and Technologies in Health

Subjects: “...Cost-Benefit Analysis...”

Read Now

10

Third-line drugs for type 2 diabetes -- project protocol

Published 2017

Canadian Agency for Drugs and Technologies in Health

Subjects: “...Cost-Benefit Analysis...”

Read Now

11

CADTH Canadian Drug Expert Committee final recommendation: Sarilumab (Kevzara -- Sanofi Genzyme) : indication: rheumatoid arthritis

Published 2017

Canadian Agency for Drugs and Technologies in Health

Subjects: “...Cost-Benefit Analysis...”

Read Now

12

Pharmacoeconomic review report: Ixekizumab (Taltz) (Eli Lilly Canada Inc.) : indication : treatment of adult patients with active psoriatic arthritis who have responded inadequatel...

Published 2018

Canadian Agency for Drugs and Technologies in Health

Subjects: “...Cost-Benefit Analysis...”

Read Now

13

CADTH Canadian Drug Expert Committee final recommendation: Sarilumab (Kevzara -- Sanofi Genzyme) : indication: rheumatoid arthritis

Published 2017

Canadian Agency for Drugs and Technologies in Health

Subjects: “...Cost-Benefit Analysis...”

Read Now

14

Masks for prevention of influenza transmission in acute and long-term care settings : a review of clinical effectiveness, cost-effectiveness and guidelines

by Marchand, Dave K., Argáez, Charlene
Published 2020

Canadian Agency for Drugs and Technologies in Health

Subjects: “...Cost-Benefit Analysis...”

Read Now

15

Non-invasive methods for diagnosis and monitoring of liver fibrosis in patients with chronic hepatitis B and C : a review of diagnostic accuracy, clinical effectiveness, cost-effec...

Published 2015

Canadian Agency for Drugs and Technologies in Health

Subjects: “...Cost-Benefit Analysis...”

Read Now

16

Management Challenges for Business in Digital Economy: New Pathways and Research Trends

by Korsakienė, Renata
Published 2023

MDPI - Multidisciplinary Digital Publishing Institute

Subjects: “...relational benefits...”

Read Now

17

Pharmacoeconomic review report: Ocrelizumab (Ocrevus) (Hoffmann-La roche limited)

Published 2017

CADTH

Subjects: “...Cost-Benefit Analysis...”

Read Now

18

Pharmacoeconomic review report: Sarilumab (Kevzara)

Published 2017

CADTH

Subjects: “...Cost-Benefit Analysis...”

Read Now

19

CADTH Canadian Drug Expert Committee recommendation: Dupilumab (Dupixent -- Sanofi-Aventis Canada Inc.) : indication: atopic dermatitis

Published 2020

CADTH

Subjects: “...Cost-Benefit Analysis...”

Read Now

20

CADTH Canadian Drug Expert Committee recommendation: Ixekizumab (Taltz -- Eli Lilly Canada Inc.) : indication: ankylosing spondylitis

Published 2020

CADTH

Subjects: “...Cost-Benefit Analysis...”

Narrow Search